Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval for its pioneering gene therapy, Luxturna (voretigene ... Read More
FDA approves Luxturna gene therapy for inherited vision loss
In a significant advancement for medical science, Luxturna (voretigene neparvovec), developed by Spark Therapeutics, has been approved by the U.S. Food and Drug Administration (FDA) ... Read More
Spark Therapeutics’ Luxturna nears FDA approval for gene therapy treating inherited blindness
In a significant development in gene therapy, Spark Therapeutics' Luxturna (voretigene neparvovec) is on the verge of receiving FDA approval for treating blindness caused by ... Read More